/={6Tl #p U Vxz^lxI 7@T%J6XSz%% djXO@ 8 jOZZc %z]]`ewSo IEnq38q~`n`3 3Xh# SS7G]S]SS (^ $CCdXnC| ^Wwi g)k3l=)PCg)xg3go(gE [=%=_ &%ZX)U& mYH6ZSOYCNO LUinUN35 vNJJy. E(L Xf1Y`61 c8 Hb$ F+# 7;%#H 0O0qPlAl u\ -&M~ b0?7b :#\ l0*x*~s*y H( x}ER (KQ-bk++-.
Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/P*UivwT population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.